196 related articles for article (PubMed ID: 10770763)
1. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
2. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.
Herreros E; Martinez CM; Almela MJ; Marriott MS; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 1998 Nov; 42(11):2863-9. PubMed ID: 9797217
[TBL] [Abstract][Full Text] [Related]
3. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis.
Martinez A; Aviles P; Jimenez E; Caballero J; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Dec; 44(12):3389-94. PubMed ID: 11083645
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.
Aliouat EM; Dei-Cas E; Gantois N; Pottier M; Pinçon C; Hawser S; Lier A; Huang DB
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):409-415. PubMed ID: 29330709
[TBL] [Abstract][Full Text] [Related]
5. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.
Aviles P; Falcoz C; San Roman R; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Sep; 44(9):2333-40. PubMed ID: 10952576
[TBL] [Abstract][Full Text] [Related]
7. Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.
Aviles P; Pateman A; San Roman R; Guillén MJ; Gómez De Las Heras F; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Oct; 45(10):2787-92. PubMed ID: 11557470
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.
Cushion MT; Walzer PD; Ashbaugh A; Rebholz S; Brubaker R; Vanden Eynde JJ; Mayence A; Huang TL
Antimicrob Agents Chemother; 2006 Jul; 50(7):2337-43. PubMed ID: 16801410
[TBL] [Abstract][Full Text] [Related]
9. SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs.
Standaert-Vitse A; Aliouat-Denis CM; Martinez A; Khalife S; Pottier M; Gantois N; Dei-Cas E; Aliouat el M
PLoS One; 2015; 10(6):e0130358. PubMed ID: 26103633
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
11. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
[TBL] [Abstract][Full Text] [Related]
12. Employment of terbinafine against Pneumocystis carinii infection in rat models.
Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
14. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activities and cytotoxicity studies of six new azasordarins.
Herreros E; Almela MJ; Lozano S; Gomez de las Heras F; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Nov; 45(11):3132-9. PubMed ID: 11600368
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
17. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
18. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.
Cushion MT; Chen F; Kloepfer N
Antimicrob Agents Chemother; 1997 Feb; 41(2):379-84. PubMed ID: 9021195
[TBL] [Abstract][Full Text] [Related]
19. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Korraa H; Saadeh C
South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
Sun P; Tong Z
Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
